Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.g

Eye-catcher: Cement (pulmonary) embolism

Publications

Papiamonis NE, Matrella E, Blevrakis EG, Kouroumalis EA

Acute pulmonary embolism following -butyl-cyanoacrylate endoscopic injection sclerotherapy.

Annals of gastroenterology 2012;25;261 — 2012 — 261

Conway R, Aglan A, O'Connor E

Severe respiratory failure due to embolization of cyanoacrylate sclerosant.

QJM : monthly journal of the Association of Physicians 2014 Oct;107;831-2 — 2014 Oct — 831-2

Alexander S, Korman MG, Sievert W

Cyanoacrylate in the treatment of gastric varices complicated by multiple pulmonary emboli.

Internal medicine journal 2006 Jul;36;462-5 — 2006 Jul — 462-5

van Beek AP, van Erpecum KJ

Fatal N-butyl-2-cyanoacrylate pulmonary embolism after sclerotherapy for variceal bleeding.

Endoscopy 2005 Jul;37;687 — 2005 Jul — 687